Jupiter Neurosciences Launches Nugevia MND: A Clinically Validated Cognitive Health Supplement

Jupiter Neurosciences introduces Nugevia MND, a cognitive health supplement combining proprietary resveratrol-based platform and NovaSOL Curcumin to enhance cognitive performance and support neuroprotective health. The supplement targets multiple neuroprotective pathways and aims to address the surging consumer demand for clinically validated cognitive wellness solutions. The company plans to use biomarker data from its upcoming Phase II Parkinson's disease trial to inform future cognitive health programs.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company, has introduced Nugevia MND, a cognitive health supplement designed to enhance cognitive performance and support neuroprotective health. The supplement combines Jupiter's proprietary JOTROL™ resveratrol technology with NovaSOL® Curcumin, targeting multiple neuroprotective pathways to address the surging consumer demand for clinically validated cognitive wellness solutions.

Nugevia MND uniquely combines Jupiter's JOTROL™ resveratrol technology, which significantly improves bioavailability and central nervous system penetration, with NovaSOL® Curcumin, a highly bioavailable curcumin formulation proven effective in supporting cognitive resilience and neuroprotection. This innovative pairing targets multiple neuroprotective pathways, including reducing oxidative stress, inflammation, and supporting synaptic plasticity, thereby promoting enhanced cognitive health.

The product is expected to generate high-margin revenue by targeting adults seeking to maintain and enhance cognitive performance, particularly amidst aging populations increasingly impacted by cognitive decline. It also strategically complements Jupiter's therapeutic pipeline, creating synergies between consumer and pharmaceutical segments.

Christer Rosén, Chairman and CEO of Jupiter Neurosciences, emphasized the personal significance of the product, citing family experiences with Alzheimer's and Parkinson's diseases. He stated, "My mother passed away from Alzheimer’s Disease making this particular product one that holds a deep sense of obligation and importance to me. Additionally, Jupiter’s former CFO ultimately lost his fight to Parkinson’s Disease. This is personal, this is important and based on our JOTROL pharmaceutical pre-clinical and clinical data we are here to bring what we believe is the best cognition product to the market."

The introduction of Nugevia MND represents a strategic move for Jupiter Neurosciences to generate high-margin revenue while complementing its pharmaceutical pipeline. The company plans to leverage consumer usage data alongside biomarker data from its upcoming Phase II Parkinson's disease trial to inform future cognitive health programs. MND will be commercially available through direct-to-consumer e-commerce platforms starting Fall 2025 as a convenient two-capsule daily regimen.

References:
[1] https://finance.yahoo.com/news/jupiter-neurosciences-introduces-nugevia-mnd-120000788.html
[2] https://www.stocktitan.net/news/JUNS/jupiter-neurosciences-introduces-nugevia-tm-mnd-a-cognitive-health-79cm2w84n95a.html